Always great to see a treatment mature from the lab to clinical trials to a write-up in The Atlantic. This is about post-transplant cyclophosphamide, initially developed at Hopkins for haploidentical (“half-matched”) stem cell transplants, now used even for full matches as it works so well in preventing graft versus host disease. Cheap as chips too, if you can get it (but of course low price and short supply are closely related).